Can Cosentyx (secukinumab) cause ulcerative colitis?

From the Guidelines

Coccentyx does not cause ulcerative colitis, and the management of moderate to severe ulcerative colitis should follow the AGA clinical practice guidelines, which recommend using biologic agents such as infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, or ustekinumab over no treatment. The guidelines suggest that the choice of biologic agent should be based on the patient's disease severity, medical history, and personal preferences, with infliximab or vedolizumab being suggested for induction of remission in biologic-naive patients 1.

Key Points to Consider

• Ulcerative colitis is an inflammatory bowel disease caused by an abnormal immune response, and its management should focus on reducing inflammation and inducing remission.
• Biologic agents have been shown to be effective in inducing and maintaining remission in patients with moderate to severe ulcerative colitis, and their use is recommended by the AGA guidelines 1.
• The choice of biologic agent should be individualized based on patient-specific factors, and patients should be closely monitored for response to treatment and potential side effects.
• There is no established causal relationship between Coccentyx and ulcerative colitis, and the use of Coccentyx is not recommended for the treatment of ulcerative colitis.

Treatment Approach

• Patients with moderate to severe ulcerative colitis should be treated with biologic agents, such as infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, or ustekinumab, as recommended by the AGA guidelines 1.
• The treatment approach should be individualized based on patient-specific factors, including disease severity, medical history, and personal preferences.
• Patients should be closely monitored for response to treatment and potential side effects, and adjustments to the treatment plan should be made as needed.

From the Research

Ulcerative Colitis and Coccentyx

• There is no direct evidence in the provided studies that links Coccentyx to causing ulcerative colitis 2, 3, 4, 5, 6.
• The studies focus on the treatment and management of ulcerative colitis, including the use of mesalamine, corticosteroids, and other medications 2, 3, 4, 5, 6.
• Ulcerative colitis is a chronic inflammatory condition of the large bowel, and its exact cause is still unclear 2, 3.
• The diagnosis of ulcerative colitis is made by combining clinical presentation, endoscopic findings, histology, and the absence of alternative diagnoses 3.

Treatment of Ulcerative Colitis

• Mesalamine is a commonly used medication for the treatment of mild to moderate ulcerative colitis 2, 5.
• Corticosteroids are used to treat acute severe ulcerative colitis, and the addition of mesalamine may not provide additional benefits 6.
• The goal of treatment is to improve quality of life, achieve steroid-free remission, and minimize the risk of cancer 3.

Medications Used to Treat Ulcerative Colitis

• Mesalamine is effective in inducing and maintaining remission in patients with ulcerative colitis 2, 5.
• Corticosteroids are effective in treating acute severe ulcerative colitis, but their long-term use can be hazardous 4.
• Other medications, such as azathioprine and mercaptopurine, may be used to maintain remission in patients with chronically active or corticosteroid-dependent disease 4.